NYSE:BHC Bausch Health Companies (BHC) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free BHC Stock Alerts $9.09 -0.19 (-2.05%) (As of 03/14/2024 ET) Add Compare Share Share Today's Range$9.04▼$9.2750-Day Range$7.77▼$9.8952-Week Range$5.57▼$10.15Volume1.03 million shsAverage Volume2.41 million shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice Target$11.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Bausch Health Companies alerts: Email Address Bausch Health Companies MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside26.5% Upside$11.50 Price TargetShort InterestBearish6.91% of Float Sold ShortDividend StrengthN/ASustainability-1.42Upright™ Environmental ScoreNews Sentiment0.61Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth2.55%From $3.92 to $4.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.31 out of 5 starsMedical Sector553rd out of 961 stocksPharmaceutical Preparations Industry241st out of 415 stocks 3.2 Analyst's Opinion Consensus RatingBausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.50, Bausch Health Companies has a forecasted upside of 26.5% from its current price of $9.09.Amount of Analyst CoverageBausch Health Companies has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.91% of the float of Bausch Health Companies has been sold short.Short Interest Ratio / Days to CoverBausch Health Companies has a short interest ratio ("days to cover") of 10.5, which indicates bearish sentiment.Change versus previous monthShort interest in Bausch Health Companies has recently increased by 14.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBausch Health Companies does not currently pay a dividend.Dividend GrowthBausch Health Companies does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBausch Health Companies has received a 55.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Allergy eye drops", "Anti-diarrheal and intestinal anti-inflammatory medication (A07)", "Laxatives", and "Intraocular lenses" products. See details.Environmental SustainabilityThe Environmental Impact score for Bausch Health Companies is -1.42. Previous Next 2.6 News and Social Media Coverage News SentimentBausch Health Companies has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bausch Health Companies this week, compared to 4 articles on an average week.Search Interest40 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat Follows8 people have added Bausch Health Companies to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch Health Companies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Bausch Health Companies is held by insiders.Percentage Held by Institutions74.56% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Bausch Health Companies are expected to grow by 2.55% in the coming year, from $3.92 to $4.02 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bausch Health Companies is -5.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bausch Health Companies is -5.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About Bausch Health Companies Stock (NYSE:BHC)Bausch Health Companies Inc. operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was incorporated in 2013 and is headquartered in Laval, Canada.Read More BHC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHC Stock News HeadlinesMarch 11, 2024 | finance.yahoo.comBHC Mar 2024 5.500 callMarch 6, 2024 | finance.yahoo.comBausch Health Companies Inc. (BHC)March 15, 2024 | Huge Alerts (Ad)A Uranium Rally May Push This Uranium-focused Stock HigherThis little-known uranium company may soon pack a nuclear punch if uranium prices continue to rally.March 6, 2024 | finanznachrichten.deSalix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell CarcinomaFebruary 28, 2024 | businesswire.comBausch + Lomb Announces Appointment of Karen L. Ling to Board of DirectorsFebruary 24, 2024 | seekingalpha.comBausch Health: A Timely Divestiture Is The Key To An Higher ValuationFebruary 22, 2024 | marketwatch.comBausch Health 4Q Loss Narrows, Revenue Growth Tops AnalystsFebruary 21, 2024 | msn.comBausch + Lomb Offers Upbeat 2024 Revenue Outlook as Fourth-Quarter Results Exceed ViewsMarch 15, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)February 21, 2024 | msn.comBausch Health Companies Q4 2023 Earnings PreviewFebruary 21, 2024 | finance.yahoo.comCompared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key MetricsFebruary 21, 2024 | businesswire.comBausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 GuidanceFebruary 21, 2024 | forbes.comElevated Interest Rates Will Push Corporate Default Rates HigherFebruary 20, 2024 | finance.yahoo.comAnalysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out forFebruary 15, 2024 | finance.yahoo.comAnalysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out forFebruary 14, 2024 | finance.yahoo.comWill Bausch + Lomb (BLCO) Beat Estimates Again in Its Next Earnings Report?February 12, 2024 | finance.yahoo.comSalix Announces 2024 Gastrointestinal Health Scholars ProgramFebruary 7, 2024 | msn.comBausch (BHC) Upgraded to Strong Buy: What Does It Mean for the Stock?February 1, 2024 | msn.comBuyer Beware: These 3 Stocks Could Seriously TumbleFebruary 1, 2024 | marketwatch.comBausch Health Nominates Two Independent Candidates to Join BoardJanuary 30, 2024 | finance.yahoo.comCABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.January 18, 2024 | finance.yahoo.comCORRECTION BY SOURCE: Solta Medical's Thermage(R) FLX and TR-4 Return Pad Receive Registration Certifications in ChinaJanuary 8, 2024 | msn.comBausch Health gains after an appeals hearing in Norwich case over generic XifaxanJanuary 1, 2024 | theglobeandmail.comClosing Bell: Bausch Health Companies Inc flat on Friday (BHC)December 18, 2023 | finance.yahoo.comAre Medical Stocks Lagging Bausch Health (BHC) This Year?December 18, 2023 | finance.yahoo.comAre Medical Stocks Lagging Bausch Health (BHC) This Year?December 18, 2023 | finanznachrichten.deBausch Health Companies Inc.: DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug PlanSee More Headlines Receive BHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today3/14/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:BHC CUSIPN/A CIK885590 Webwww.bauschhealth.com Phone(514) 744-6792Fax514-744-6272Employees20,270Year FoundedN/APrice Target and Rating Average Stock Price Target$11.50 High Stock Price Target$14.00 Low Stock Price Target$9.00 Potential Upside/Downside+26.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.62) Trailing P/E RatioN/A Forward P/E Ratio2.32 P/E GrowthN/ANet Income$-592,000,000.00 Net Margins-6.76% Pretax Margin-4.45% Return on Equity5,147.48% Return on Assets4.84% Debt Debt-to-Equity Ratio74.20 Current Ratio1.30 Quick Ratio0.94 Sales & Book Value Annual Sales$8.76 billion Price / Sales0.38 Cash Flow$7.21 per share Price / Cash Flow1.26 Book Value($0.23) per share Price / Book-39.52Miscellaneous Outstanding Shares365,410,000Free Float338,737,000Market Cap$3.32 billion OptionableOptionable Beta0.83 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Thomas J. Appio (Age 62)CEO & Director Comp: $4.73MMs. Seana Carson (Age 52)Executive VP & General Counsel Comp: $720.5kMr. John S. Barresi (Age 51)Senior VP, Controller, Chief Accounting Officer & Interim CFO Mr. Mirza DautbegovicSenior VP & COOMr. Josh CoyleSenior Vice President of Sales & SalixMs. Kathleen FitzpatrickSenior VP & Chief HR OfficerDr. Tage Ramakrishna M.D. (Age 50)Chief Medical Officer and President of R&D Mr. Jeff HartnessExecutive VP of Market Access, Commercial Operations, Neurology, Generics & Government AffairsDr. Graham JacksonSenior VP & Chief Quality OfficerMr. Cees HeimanSenior Vice President of Europe & CanadaMore ExecutivesKey CompetitorsXenon PharmaceuticalsNASDAQ:XENEIDEAYA BiosciencesNASDAQ:IDYAACADIA PharmaceuticalsNASDAQ:ACADAmicus TherapeuticsNASDAQ:FOLDArrowhead PharmaceuticalsNASDAQ:ARWRView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 111,363 shares on 3/11/2024Ownership: 3.174%Goldman Sachs Group Inc.Bought 132,237 shares on 3/1/2024Ownership: 0.401%Virtu Financial LLCBought 15,873 shares on 2/26/2024Ownership: 0.004%Readystate Asset Management LPBought 365,761 shares on 2/20/2024Ownership: 0.100%Public Employees Retirement System of OhioBought 13,076 shares on 2/16/2024Ownership: 0.041%View All Insider TransactionsView All Institutional Transactions BHC Stock Analysis - Frequently Asked Questions Should I buy or sell Bausch Health Companies stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares. View BHC analyst ratings or view top-rated stocks. What is Bausch Health Companies' stock price target for 2024? 3 brokers have issued 12 month price targets for Bausch Health Companies' shares. Their BHC share price targets range from $9.00 to $14.00. On average, they expect the company's stock price to reach $11.50 in the next year. This suggests a possible upside of 26.5% from the stock's current price. View analysts price targets for BHC or view top-rated stocks among Wall Street analysts. How have BHC shares performed in 2024? Bausch Health Companies' stock was trading at $8.02 on January 1st, 2024. Since then, BHC stock has increased by 13.3% and is now trading at $9.09. View the best growth stocks for 2024 here. Are investors shorting Bausch Health Companies? Bausch Health Companies saw a increase in short interest in February. As of February 29th, there was short interest totaling 24,640,000 shares, an increase of 14.4% from the February 14th total of 21,530,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is presently 10.5 days. Currently, 6.9% of the shares of the stock are sold short. View Bausch Health Companies' Short Interest. When is Bausch Health Companies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BHC earnings forecast. How were Bausch Health Companies' earnings last quarter? Bausch Health Companies Inc. (NYSE:BHC) released its earnings results on Thursday, February, 22nd. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.01 by $0.14. The company had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive trailing twelve-month return on equity of 5,147.48%. The firm's quarterly revenue was up 9.8% compared to the same quarter last year. During the same period last year, the business earned $1.02 EPS. What guidance has Bausch Health Companies issued on next quarter's earnings? Bausch Health Companies issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $9.3 billion-$9.3 billion, compared to the consensus revenue estimate of $9.0 billion. What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO? 43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Bausch Health Companies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC). Who are Bausch Health Companies' major shareholders? Bausch Health Companies' stock is owned by many different institutional and retail investors. Top institutional investors include National Bank of Canada FI (4.34%), Nomura Holdings Inc. (3.68%), Healthcare of Ontario Pension Plan Trust Fund (3.60%), Royal Bank of Canada (3.25%), Vanguard Group Inc. (3.21%) and Vanguard Group Inc. (3.17%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson and Steven D Miller. View institutional ownership trends. How do I buy shares of Bausch Health Companies? Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:BHC) was last updated on 3/15/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsThe Top Uranium Stock for Your 2024 Watch ListHuge AlertsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingWhy Wall Street is SELLING NvidiaChaikin AnalyticsNext President (Not Trump. Not Biden.)The Freeport SocietyUrgent new message from Porter StansberryPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch Health Companies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.